钠葡萄糖协同转运蛋白2抑制剂在心律失常中的研究进展

娜迪 热·, 麦迪 乃·, 严 金龙
新疆医科大学第二附属医院心血管内科 新疆乌鲁木齐市 830000

摘要

目的：心律失常作为常见的心血管疾病，会降低患者生活质量、增加医疗卫生资源的消耗，但目前仍缺乏有效并能长期应用的治疗药物。近几年被高度重视的钠葡萄糖协同转运蛋白2抑制剂(sodium-glucosecotransporter2inhibitor，SGLT2i)，此类药物目前除了降糖以外，还具有强大的心血管益处，通过大型临床研究已成为慢性射血分数降低型心力衰竭患者一线治疗药物。此外，最近的基础研究和临床研究也报道了SGLT2i类药物良好的抗心律失常作用。本文回顾了近期SGLT2i有关抗心律失常作用的实验研究及临床发现，对此做一综述。

关键词

钠葡萄糖协同转运蛋白2抑制剂(SGLT2i)；心律失常；房性心律失常；室性心律失常

参考

[1]January CT,Wann LS,Calkins H,et al.2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society[J].Heart Rhythm,2019,16(8):e66-e93.[2]Zeppenfeld K,Tfelt-Hansen J,De Riva M,et al.2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death [J]. Eur Heart J,2022,43(40):3997-4126.[3]Mohammad NS, Nazli R, Zafar H,et al.Effects of lipid based Multiple Micronutrients Supplement on the birth outcome of underweight pre-eclamptic women:A randomized clinical trial[J].Pak J Med Sci,2022,38(1):219-26.[4]Zelniker T A,Braunwald E. Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review [J]. J Am Coll Cardiol, 2018, 72(15): 1845-55.[5]Lawler P R,Bhatt D L,Godoy L C, et al. Targeting cardiovascular inflammation: next steps in clinical translation [J]. Eur Heart J, 2021, 42(1): 113-31.[6]Fernandes G C,Fernandes A,Cardoso R, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials [J]. Heart Rhythm, 2021, 18(7): 1098-105.[7]Heerspink HJL, Perco P, Mulder S, et al. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease [J]. Diabetologia, 2019, 62(7): 1154-66.[8]Xue L,Yuan X,Zhang S, et al. Investigating the Effects of Dapagliflozin on Cardiac Function, Inflammatory Response, and Cardiovascular Outcome in Patients with STEMI Complicated with T2DM after PCI [J]. Evid Based Complement Alternat Med, 2021, 2021: 9388562.[9]Kang S,Verma S,Hassanabad AF, et al.Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results. Can J Cardiol. 2020,36(4):543-553.[10]Baartscheer A, Schumacher C A, Wüst R C, et al. Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits [J]. Diabetologia, 2017, 60(3): 568-73.[11]Emdin CA, Anderson SG,Salimi-Khorshidi G, et al. Usual blood pressure, atrial fibrillation and vascular risk: evidence from 4.3 million adults [J]. Int J Epidemiol, 2017, 46(1): 162-72.[12]Sano M. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity [J]. J Cardiol, 2018, 71(5): 471-6.[13]Iacobellis G,Gra-Menendez S. Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity [J]. Obesity (Silver Spring), 2020, 28(6): 1068-74.[14]Cosentino F,Grant P J,Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD [J].Eur Heart J, 2020, 41(2): 255-323.[15]Patel K H K,Hwang T,Se Liebers C, et al. Epicardial adipose tissue as a mediator of cardiac arrhythmias [J]. Am J Physiol Heart CircPhysiol, 2022, 322(2): H129-h44.[16]Bonora B M,Raschi E,Avogaro A, et al. SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system [J]. Cardiovasc Diabetol, 2021, 20(1): 39.[17]Zelniker T A,Bonaca M P,Furtado R H M, et al. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial [J]. Circulation, 2020, 141(15): 1227-34.[18]Tanaka H,Tatsumi K,Matsuzoe H, et al. Association of type 2 diabetes mellitus with the development of new-onset atrial fibrillation in patients with non-ischemic dilated cardiomyopathy: impact of SGLT2 inhibitors [J]. Int J Cardiovasc Imaging, 2021, 37(4): 1333-41.[19]Okunrintemi V,Mishriky B M,Powell J R, et al. Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials [J]. Diabetes Obes Metab, 2021, 23(1): 276-80.[20]Shen L,Jhund P S,Petrie M C, et al. Declining Risk of Sudden Death in Heart Failure [J]. N Engl J Med, 2017, 377(1): 41-51.[21]Ilyas F,Jones L,Tee S L, et al. Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial [J]. ESC Heart Fail, 2021, 8(5): 4346-52.[22]Curtain J P,Docherty K F,Jhund P S, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF [J]. Eur Heart J, 2021, 42(36): 3727-38.